PARLIAMENTARY WRITTEN QUESTION
(19 May 2025)
Question Asked
Asked by:
Steff Aquarone (Liberal Democrat)
Answer
The supply of methylphenidate prolonged-release tablets has greatly improved. However, some issues persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets and capsules to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to build further capacity to support continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets and capsules to improve the supply and resiliency for the United Kingdom’s market.
The Department continually updates a list of currently available and unavailable attention deficit hyperactivity disorder (ADHD) products on the Specialist Pharmacy Service website. This helps ensure those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients. This list is available at the following link:
www.sps.nhs.uk/articles/prescribing-available-medicines-to-treat-adhd
The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information on stock levels within Norfolk is not held centrally.
Answered by:
()
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.